Akebia Therapeutics Appoints Biopharmaceutical Leader to Board

Philip Vickers, Ph.D. joins the board of the Cambridge-based biotech company.

Apr. 1, 2026 at 11:29pm

Got story updates? Submit your updates here. ›

Akebia Therapeutics, a publicly-traded biopharmaceutical company based in Cambridge, Massachusetts, has appointed Philip Vickers, Ph.D. to its board of directors. Vickers is an experienced leader in the biotech industry, having held executive roles at several major pharmaceutical companies.

Why it matters

Akebia Therapeutics is a key player in the Cambridge biotech ecosystem, developing treatments for kidney disease and other conditions. Appointing an industry veteran like Vickers to the board signals the company's commitment to growth and innovation as it navigates the competitive biopharmaceutical landscape.

The details

Vickers previously served as the Head of Research and Development and Chief Scientific Officer at Shire Pharmaceuticals. Prior to that, he held leadership positions at Eli Lilly and Pfizer. In his new role on Akebia's board, Vickers will provide strategic guidance and oversight as the company advances its clinical pipeline and explores new therapeutic areas.

  • Akebia Therapeutics announced the board appointment on April 1, 2026.

The players

Akebia Therapeutics

A publicly-traded biopharmaceutical company based in Cambridge, Massachusetts that develops treatments for kidney disease and other conditions.

Philip Vickers, Ph.D.

An experienced biopharmaceutical executive who has held leadership roles at companies like Shire Pharmaceuticals, Eli Lilly, and Pfizer.

Got photos? Submit your photos here. ›

What they’re saying

“We are thrilled to welcome Philip to our board of directors. His deep expertise in drug development and commercialization will be invaluable as we continue to grow Akebia and advance our pipeline of innovative therapies.”

— John P. Butler, President and Chief Executive Officer of Akebia Therapeutics

The takeaway

Akebia's appointment of an industry veteran like Philip Vickers to its board underscores the company's ambitions to expand its reach and impact within the competitive biopharmaceutical landscape.